drugset / Trial / NCT00985855

Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

NCT00985855 ↗

Phase 2 Completed 91 enrolled Institut de Cancérologie de la Loire
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase II, randomised, controlled, non comparative study with 2 parallel groups: * Arm A: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemotherapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy. * Arm B: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.

Timeline

Start
2009-09
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 50 mg/m2 —
Subject Cisplatin Other / unclassified 80 mg/m2 —
Subject Etoposide Small molecule 50 mg/m2 —
Subject Vinorelbine Small molecule 15 mg/m2 —
Background Cetuximab Monoclonal antibody 400 mg/m2 Other